Landscape Capital Management L.L.C. Invests $1.38 Million in Amgen Inc. (NASDAQ:AMGN)

Landscape Capital Management L.L.C. purchased a new position in Amgen Inc. (NASDAQ:AMGN) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 5,310 shares of the medical research company’s stock, valued at approximately $1,384,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Quantbot Technologies LP bought a new stake in Amgen during the third quarter valued at $150,000. Texas Capital Bank Wealth Management Services Inc raised its stake in Amgen by 144.0% during the third quarter. Texas Capital Bank Wealth Management Services Inc now owns 1,747 shares of the medical research company’s stock worth $563,000 after acquiring an additional 1,031 shares during the period. Two Sigma Advisers LP lifted its holdings in Amgen by 9.5% in the third quarter. Two Sigma Advisers LP now owns 784,900 shares of the medical research company’s stock worth $252,903,000 after acquiring an additional 68,000 shares during the last quarter. Wellington Management Group LLP boosted its stake in Amgen by 2.1% in the third quarter. Wellington Management Group LLP now owns 239,354 shares of the medical research company’s stock valued at $77,122,000 after acquiring an additional 4,942 shares during the period. Finally, Kovitz Investment Group Partners LLC grew its holdings in shares of Amgen by 38.0% during the third quarter. Kovitz Investment Group Partners LLC now owns 93,668 shares of the medical research company’s stock valued at $30,181,000 after purchasing an additional 25,806 shares during the last quarter. 76.50% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. Royal Bank of Canada reissued an “outperform” rating and issued a $324.00 price target on shares of Amgen in a report on Friday, January 24th. UBS Group reissued a “hold” rating on shares of Amgen in a report on Wednesday, February 12th. Piper Sandler Companies reaffirmed an “overweight” rating and issued a $310.00 price objective on shares of Amgen in a report on Thursday, January 2nd. Wells Fargo & Company reissued an “equal weight” rating on shares of Amgen in a research note on Wednesday, February 5th. Finally, Truist Financial dropped their price target on shares of Amgen from $333.00 to $298.00 and set a “hold” rating on the stock in a research note on Wednesday, January 8th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Amgen presently has a consensus rating of “Moderate Buy” and an average price target of $314.04.

Amgen Price Performance

NASDAQ AMGN opened at $294.39 on Friday. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85. The stock’s 50-day moving average price is $304.18 and its two-hundred day moving average price is $297.49. The company has a market cap of $158.15 billion, a PE ratio of 38.99, a PEG ratio of 2.63 and a beta of 0.53. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, beating the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. On average, analysts predict that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be paid a $2.38 dividend. This represents a $9.52 annualized dividend and a yield of 3.23%. The ex-dividend date of this dividend is Friday, May 16th. Amgen’s dividend payout ratio is currently 126.09%.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,589 shares of the stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total value of $483,802.83. Following the completion of the sale, the senior vice president now owns 7,210 shares in the company, valued at $2,195,228.70. This represents a 18.06 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Murdo Gordon sold 8,771 shares of the business’s stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $294.79, for a total transaction of $2,585,603.09. Following the transaction, the executive vice president now owns 44,186 shares in the company, valued at approximately $13,025,590.94. This represents a 16.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 69,341 shares of company stock valued at $20,644,335 over the last three months. 0.69% of the stock is owned by corporate insiders.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.